Sexually transmitted infections at primary examination among patients attending a sexual assault centre in Oslo, Norway
| Female n/N (%) | Male n/N (%) | Total n/N (%) | |
| Chlamydia trachomatis | |||
| Patients total | 50/578 (8.7) | 2/42 (4.8) | 52/620 (8.4) |
| Cervix/vagina/urethra/urine* | 49/573 (8.6) | 0/42* | 49/615 (8.0) |
| Anus | 12/243 (4.9) | 2/30 (6.7) | 14/273 (5.1) |
| Mycoplasma genitalium | |||
| Patients total | 34/494 (6.9)† | 0/35 | 34/529 (6.4)† |
| Cervix/vagina/urethra/urine* | 28/490 (5.7)‡ | 0/34 | 28/524 (5.3)‡ |
| Anus | 8/212 (3.8)§ | 0/25 | 8/237 (3.4)§ |
| Neisseria gonorrhoeae | |||
| Patients total | 4/593 (0.7) | 0/42 | 4/635 (0.6) |
| Cervix/vagina/urethra/urine* | 2/573 (0.3) | 0/41 | 2/614 (0.3%) |
| Anus | 1/238 (0.4) | 0/30 | 1/268 (0.4) |
| Oropharynx | 4/522 (0.8) | 0/36 | 4/558 (0.7) |
| Hepatitis B | |||
| Known chronic contagious infection | 1/584 (0.2) | 1/42 (2.4) | 2/626 (0.3) |
| Previous infection | 10/584 (1.7) | 1/42 (2.4) | 11/626 (1.8) |
| Previously vaccinated | 181/584 (31.0) | 15/42 (35.7) | 196/626 (31.3) |
| Positive vaccination status during follow-up¶ | 360/420 (85.7) | 24/32 (75.0) | 384/452 (85.0) |
| Hepatitis C | |||
| Known previous infection | 12/585 (2.1) | 2/42 (4.8) | 14/627 (2.2) |
| HIV | |||
| Known infection | 1/586 (0.2) | 0/42 | 1/628 (0.2) |
| Syphilis | |||
| Known previous infection | 1/576 (0.2) | 2/39 (5.1)* | 3/615 (0.5) |
Proportions stated as positive tests (n) per patient tested (N).
Fourteen patients were tested for lymphogranuloma venereum, all negative.
Seven patients were tested for Trichomonas vaginalis, all negative.
No condylomas were diagnosed (visual inspection).
Comparisons between sexes: *p<0.05; **p<0.01; ***p<0.001.
*Women sampled from cervix and/or vagina or in urine, men sampled from urethra or in urine.
†Fourteen cases macrolide resistant.
‡Twelve cases macrolide resistant.
§Four cases macrolide resistant.
¶Seroconversion assessment 3 months after primary examination.